Researchers from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have presented NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of neurodegeneration.
Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.
Scientists from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented NLRP3 inflammasome and interleukin-1β (IL1B; IL-1β) release inhibitors reported to be useful for the treatment of ...
AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback